Featured Research

Could drugs prevent Alzheimer’s? These trials aim to find out

Trial coordinator Eric McDade assesses participant Marty Reiswig for cognitive ability.Credit: Matt Miller/Washington University School of Medicine
View Content

Every two weeks, a nurse visits 43-year-old Marty Reiswig in Denver, Colorado, and injects him with an experimental drug called gantenerumab. Every month, Reiswig drives into town for a brain scan to make sure the drug has not caused any bleeds. And every year he flies to St Louis, Missouri, for four days of brain scans, spinal taps, blood analyses and exhaustive tests of his memory and reasoning capacity.